Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence – A Global, Multicenter, Randomized, Open-label Phase 3 Study
Prevention of datopotamab deruxtecan (TROP-2 directed ADC) associated stomatitis in patients with HER2-negative metastatic breast cancer or non-small cell lung cancer using Dexamethasone Mouthwash: a single-arm, phase 2 trial (TROPION- DM, 2023-ESR-000087)
A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician’s choice chemotherapy, for the treatment of participants with metastatic HER2-positive breast cancer
Phase III Trial of Neoadjuvant Durvalumab Plus Chemotherapy Versus Chemotherapy Alone for Adults with UltraHigh HR Positive, HER2 Negative Stage II-III Breast Cancer
A Randomized Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.
A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant compared with Fulvestrant, both combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor-Positive, HER2-NEGATIVE Advanced Breast Cacncer with Resistance to Prior Adjuvant Endocrine Therapy
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants with Selected Advanced or Metastatic Solid Tumors
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
